| Date | Title | Description |
| 03.09.2026 | ASEAN Rapid Diagnostic Test Market to Reach USD 1.36 Billion by 2030 | The ASEAN Rapid Diagnostic Test Market is valued at an estimated USD 1.08 billion in 2025 and is projected to reach USD 1.36 billion by 2030, registering a CAGR of 4.7% during the forecast period. Market growth is being driven by the rising... |
| 14.03.2025 | Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement | DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today fro... |
| 14.03.2025 | Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement | DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today fro... |
| 13.03.2025 | Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process | DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today ... |
| 28.02.2025 | Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company’s Continuous Glucose Monitoring Technology | DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced i... |
| 06.02.2025 | Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial | DUBLIN, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced new findin... |
| 28.01.2025 | Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology | DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced c... |
| 24.12.2024 | Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan | DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has ent... |
| 24.12.2024 | Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan | DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has ent... |
| 15.11.2024 | Trinity Biotech Announces Q3 2024 Financial Results | Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business
Point-of-Care product revenue of $4.3 million grew 60% Y/Y
Reiterates guidance to achieve approximately $20 million of annu... |
| 15.11.2024 | Trinity Biotech Announces Q3 2024 Financial Results | Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business
Point-of-Care product revenue of $4.3 million grew 60% Y/Y
Reiterates guidance to achieve approximately $20 million of annu... |
| 14.11.2024 | Trinity Biotech to Announce Q3 2024 Financial Results | DUBLIN, Ireland, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, w... |
| 07.11.2024 | Trinity Biotech Regains Compliance with Nasdaq Listing Requirements | DUBLIN, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announ... |
| 25.10.2024 | Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture | DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquis... |
| 25.10.2024 | Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform | DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategi... |
| 07.10.2024 | Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology | DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the succes... |
| 24.09.2024 | Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market | -Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women-
-The PrePsia test can predict preeclampsia r... |
| 18.09.2024 | Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer | DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided an update ... |
| 09.09.2024 | Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology | DUBLIN, Ireland, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today provided a... |
| 26.08.2024 | Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales | DUBLIN, Ireland, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced t... |
| 20.08.2024 | Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director | DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appoin... |
| 20.08.2024 | Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director | DUBLIN, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appoin... |
| 13.08.2024 | Trinity Biotech to Announce Q2 2024 Financial Results | DUBLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will repor... |
| 13.08.2024 | Trinity Biotech to Announce Q2 2024 Financial Results | Conference Call Scheduled for Wednesday, August 14, 2024 at 8:30 AM ET
DUBLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management sol... |
| 06.08.2024 | Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements | DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, obtained an extension to d... |
| 06.08.2024 | Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements | DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, obtained an extension to d... |
| 02.08.2024 | Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience | -Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth-
-Reiterating financial guidance of approximately $20 million of annualized run-rate EBITDASO1 on annua... |
| 02.08.2024 | Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience | -Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth-
-Reiterating financial guidance of approximately $20 million of annualized run-rate EBITDASO1 on annua... |
| 09.07.2024 | Trinity Biotech Announces Appointment of A New CFO | DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appoint... |
| 09.07.2024 | Trinity Biotech Announces Appointment of A New CFO | DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the appoint... |
| 24.06.2024 | Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor | DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced steps to ad... |
| 10.06.2024 | Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association | DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces ... |
| 10.06.2024 | Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association | DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces ... |
| 13.05.2024 | Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales | DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced tha... |
| 08.03.2024 | Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule | - |
| 15.02.2024 | Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change | DUBLIN, Ireland, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American depositary shares (“ADSs”) from one (1) ADS r... |
| 13.02.2024 | Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change | DUBLIN, Ireland, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.(NASDAQ: TRIB) (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from... |
| 08.02.2024 | Trinity Biotech to Present at Emerging Growth Conference | DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024. The Company invites individual... |
| 07.08.2023 | Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System | DUBLIN, Ireland, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Premier Resolution System, an automated analyzer for the accurate & precise quantification ... |
| 27.04.2023 | Trinity Biotech Announces the Successful Closing of the $30 Million Sale of its Life Sciences Supply Business to Biosynth | - |
| 27.04.2023 | Trinity Biotech Announces the Successful Closing of the $30 Million Sale of its Life Sciences Supply Business to Biosynth | /EIN News/ -- DUBLIN, Ireland, April 27, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, today ... |
| 22.02.2023 | Trinity Biotech Announces Entry Into An Increased Loan Facility to Fund Potential Acquisitions | /EIN News/ -- DUBLIN, Ireland, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today an... |
| 10.01.2023 | Trinity Biotech Announces Strategic Partnership with imaware to Deliver Integrated Diagnostic Testing Solutions to Digital Health Industry | Trinity Biotech, a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, announced a strategic partnership with imaware Inc that combines their built-to-partner digital health plat... |
| 26.10.2022 | Trinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors | /EIN News/ -- DUBLIN, Ireland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces the appo... |
| 26.10.2022 | Trinity Biotech Announces the Appointment of Tom Lindsay to its Board of Directors | DUBLIN, Ireland, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announces the appointment of Mr.... |
| 03.10.2022 | Trinity Biotech Announces The Appointment of Aris Kekedjian As Chairman and CEO | DUBLIN, Ireland, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the appointment of Mr.... |
| 30.09.2022 | Trinity Biotech Announces Results of AGM | DUBLIN, Ireland, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the results of an Ann... |
| 03.05.2022 | Trinity Biotech Announces the Successful Closing of its Strategic Investment and Partnership With The MiCo Group of South Korea | DUBLIN, Ireland, May 03, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has closed its ... |
| 28.01.2022 | Trinity Biotech Announces The Successful Closing of its Debt Refinancing | DUBLIN, Ireland, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has closed its... |
| 27.01.2022 | Trinity Biotech Announces The Successful Closing of its Debt Refinancing | DUBLIN, Ireland, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has closed its... |
| 09.09.2021 | Trinity Biotech Announces Results for Q2, 2021 | DUBLIN, Ireland, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quart... |
| 25.05.2021 | TRINITY BIOTECH PLC
Trinity Biotech Announces Results for Q1, 2021 | DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter... |
